Diaceutics Appoints Julie Goonewardene Chair of Its Advisory Board | Diaceutics

Diaceutics Appoints Julie Goonewardene Chair of Its Advisory Board

Diaceutics, a leading international consulting, software and service solutions company, which helps the pharmaceutical and diagnostic industries understand how to make the personalized medicine business model work for all stakeholders, has appointed Julie Goonewardene as Chairwoman of its Board of Advisors

Ms. Goonewardene is currently President of KUIC and Associate Vice Chancellor for Innovation and Entrepreneurship University of Kansas, and has a track record as an experienced entrepreneur, having co-founded and served as president and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired. Cantilever’s customers were Fortune 500 companies. Prior to Cantilever, she was president of the Strategic Systems Group (SSG), a boutique information technology consulting firm, and co-founder of Technology Solutions (TSC), a professional IT services firm which went public three years after its inception.

“I am personally delighted to have Julie come on board to help us navigate these important next few years,” said Peter Keeling, Chief Executive Officer of Diaceutics. “Like the personalized medicine business area, Diaceutics itself is undergoing tremendous transformation and growth and Julie’s experience with fast moving technology and companies in the healthcare arena is critical to our next stage of development.”

In addition to her role at KU, Ms. Goonewardene is an author, frequent speaker and consultant on entrepreneurship and innovation. Based on success in these areas, Julie was elected to the Board of Trustees for the American Medical Association (AMA), the Board of Directors of the Personalized Medicine Coalition and Matrix-Bio. As a first generation American born to Sri Lankan and Australian parents, she brings a unique global perspective to her endeavours.

Meeting the needs of personalized medicine is a significant challenge for many in the pharmaceutical and diagnostic industries. Diaceutics is building on its eight years of pioneering leadership in the area to expand its innovative services to this client base, recently adding a laboratory services arm and communications and branding services in partnership with Omnicom.

“Diaceutics is a company in the right place at the right time and I am delighted to help the management team manage this crucial next stage of corporate development,” said Ms. Goonewardene.

Julie takes over from Tiffany Olson, the company’s outgoing chairwoman who has resigned to focus on her new role as President, Nuclear Pharmacy Solutions at Cardinal Health.   “We appreciate the invaluable advice and guidance provided by Tiffany  Over the past two years and wish her well in her new role at Cardinal Health,” said Keeling.

About Diaceutics
Diaceutics is transforming an industry model by enabling pharmaceutical companies to accelerate their market penetration and achieve a better return on new therapies by helping them to revolutionise their patient testing. It does this by providing insights generated from its real-time testing data from its worldwide laboratory network, helping Pharma to understand and leverage the diagnostic landscape and deploy initiatives that aid patient diagnosis. The company has experience of more than 300 precision medicine projects and works with 31 of the world’s top 35 pharmaceutical companies. The company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries.

  • Proven global market leader with experience of 300+ precision medicine projects
  • We have helped launch 6 out of the last 12 targeted oncology brands
  • Extensive coverage of Top 10 global markets: US, France, Germany, UK, Italy, Spain, Brazil, China, Russia, Australia
  • Estimates indicate having improved testing for over 500,000 patients globally
  • We draw data from a global network of over 2,500 laboratories to facilitate diagnostic insights
  • We employ a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries

Media Contact
Rebecca McKnight
Tel: +353 1 215 7677
Email: rebecca@comit.ie
For more information, visit www.diaceutics.com or follow Diaceutics on Twitter, LinkedIn or Facebook

Latest Blogs

Latest Blogs

Facebook
Twitter
YouTube
LinkedIn